Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2Receptor Antagonist
Author:
- 1 September 2001
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 7 (3) , 265-282
Abstract
Remoxipride is a substituted benzamide that acts as a weak but very selective antagonist of dopamine D2receptors. It was introduced by Astra (Roxiam) at the end of the eighties and was prescribed as an atypical antipsychotic. This article reviews its putative selective effects on mesolimbic versus nigrostriatal dopaminergic systems. In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist‐induced hyperactivity. These findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms. Remoxipride also appears to be effective in more recent animal models of schizophrenia, such as latent inhibition or prepulse inhibition. In clinical studies, remoxipride shows a relatively low incidence of extrapyramidal side effects and its effects on prolactin release are short‐lasting and generally mild. The clinical efficacy of remoxipride is similar to that of haloperidol or chlorpromazine. Although its clinical use was severely restricted in 1993, due to reports of aplastic anemia in some patients receiving remoxipride, this drug has been found to exhibit relatively high selectivity for dopamine D2receptors making remoxipride an interesting tool for neurochemical and behavioral studies.Keywords
This publication has 126 references indexed in Scilit:
- Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic AgentCNS Drug Reviews, 2000
- Risperidone: Refining the Tools to Treat SchizophreniaCNS Drug Reviews, 1999
- Adverse Effects of Antipsychotic AgentsDrugs, 1996
- Modulation of nmda and dopaminergic neurotransmissions by sigma ligands: Possible implications for the treatment of psychiatric disordersLife Sciences, 1996
- Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the ratJournal of Neural Transmission, 1993
- Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profileJournal of Neural Transmission, 1993
- Tolerability of Remoxipride in the Long Term Treatment of SchizophreniaDrug Safety, 1993
- Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brainJournal of Neural Transmission, 1992
- RemoxiprideDrugs, 1990
- Human dopamine receptor subtypes?in vitro binding analysis using3H-SCH 23390 and3H-racloprideJournal of Neural Transmission, 1988